Q&A with Larry Kadis, Federal Equipment - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Q&A with Larry Kadis, Federal Equipment
A Q&A with Larry Kadis, President and CEO of Federal Equipment, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 6, pp. 72


Larry Kadis
How has the increasing focus on biopharmaceuticals affected your business?


Federal Equipment Company buys and sells used process and packaging equipment for the pharmaceutical industry—as the needs of the industry evolve, so will our inventory.

The challenge for Federal Equipment to serve biopharmaceutical manufacturers will be to identify equipment that has value on the secondary market. Many biopharmaceutical and protein process trains are specific to the product. For this equipment, we would need to find a company looking to manufacture that same product—this is not always easy. Equipment specifically designed to produce just one protein or product may not have much more value than scrap after its current owner is no longer using it. With that said, major pharmaceutical manufacturers are investing in biosimilar production facilities. This development fits well with Federal Equipment's business model. Historically, generic manufacturers and contract manufacturers have found a great deal of value in our inventory and services.


Do you see a new industry trend emerging?


We currently see a strong trend towards containment equipment in solid-dose manufacturing driven by potent compound development. We have seen a great increase in the development of containment solutions for both pilot scale equipment as well as production scale equipment.

We also see a great opportunity for new solutions in aseptic manufacturing and fill–finish activities. These are very complex manufacturing processes and techniques and the manufacturers have made their way into headlines and news lately because of drug shortages. There are many new products and a great deal of life-saving products in vials—equipment suppliers should be leading the way with engineered solutions to the problems this segment of the industry currently faces.

In addition, we see manufacturers showing interest in disposable equipment for production processes. This will be an interesting study in whether a process with disposable equipment components will be more efficient, cost-effective, and reliable than a process with traditional equipment.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here